Protara Therapeutics (NASDAQ:TARA) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Protara Therapeutics (NASDAQ:TARA) in a research note released on Friday morning, MarketBeat reports. The firm issued an overweight rating on the stock.

Several other brokerages have also issued reports on TARA. Guggenheim reiterated a “buy” rating and issued a $20.00 price target on shares of Protara Therapeutics in a research note on Friday, December 6th. HC Wainwright restated a “buy” rating and issued a $23.00 price objective on shares of Protara Therapeutics in a report on Thursday, March 6th. Finally, Lifesci Capital initiated coverage on Protara Therapeutics in a report on Tuesday, March 11th. They set an “outperform” rating and a $22.00 target price on the stock. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $22.50.

Protara Therapeutics Stock Performance

NASDAQ:TARA opened at $4.31 on Friday. The company has a market cap of $88.92 million, a PE ratio of -1.53 and a beta of 1.69. The stock has a 50-day simple moving average of $4.42 and a 200 day simple moving average of $3.49. Protara Therapeutics has a 52-week low of $1.60 and a 52-week high of $10.48.

Protara Therapeutics (NASDAQ:TARA) last issued its quarterly earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.09. On average, research analysts predict that Protara Therapeutics will post -3.32 earnings per share for the current fiscal year.

Institutional Trading of Protara Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Oppenheimer & Co. Inc. raised its holdings in shares of Protara Therapeutics by 40.8% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 179,125 shares of the company’s stock valued at $328,000 after purchasing an additional 51,944 shares during the period. XTX Topco Ltd acquired a new position in Protara Therapeutics during the third quarter worth approximately $60,000. Geode Capital Management LLC increased its position in Protara Therapeutics by 21.0% during the third quarter. Geode Capital Management LLC now owns 170,040 shares of the company’s stock worth $311,000 after buying an additional 29,514 shares during the last quarter. Bailard Inc. bought a new stake in Protara Therapeutics in the fourth quarter valued at approximately $157,000. Finally, Commonwealth Equity Services LLC lifted its position in shares of Protara Therapeutics by 90.4% in the fourth quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company’s stock valued at $195,000 after buying an additional 17,572 shares during the last quarter. Institutional investors and hedge funds own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.